European Commission

Woman bleeding from the nose
#CHMP #CSL #Europe #European Commission #Haemophilia #Marketing approval authorisation

EU-approved gene therapy reduced haemophilia bleeds by 64%

The European Commission has granted conditional marketing authorisation for CSL’s Hemgenix (etranacogene dezaparvovec), the first one-time gene therapy for severe and moderately severe haemophilia B (congenital Factor IX deficiency) in adults without a history of Factor IX inhibitors.   In an ongoing clinical trial, the drug reduced the… Read More

#Editor's Choice #News

Stamp of approval
#European Commission #Orphan drugs #Paediatrics #Phase III trial #Regulatory #UCB

Fenfluramine approved in the EU for LGS seizures

UCB’s Fintepla (fenfluramine) oral solution has been approved in the European Union (EU) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).  It has received authorisation as an add-on therapy to other anti-epileptic medicines for patients two years of age and older.  The approval was based on safety and… Read More

#News #Regulatory

T cell attacking cancer cell
#Atara Biotherapeutics #Epstein-Barr virus #EU #European Commission #Immunotherapy #Phase III trial #Pierre Fabre #T cell activation

First allogeneic T cell immunotherapy launched in EU

Pierre Fabre will commercialise and distribute the first approved allogeneic T cell immunotherapy in Europe following the transfer of the European Commission marketing authorisation of Ebvallo (tabelecleucel) from Atara Biotherapeutics.  Ebvallo is the only approved therapy for the treatment of relapsed or refractory Epstein‑Barr virus positive post‑transplant lymphoproliferative disease (EBV+… Read More

#Business & Investment #News

Mammography
#Breast cancer #Cancer research #European Commission #Gene mutation #Genetics / genomes #HER2 #Oncology

Drug approved for breast cancer with low levels of HER2 expression

Enhertu has been approved in the EU as the first HER2 directed therapy for patients with HER2 low metastatic breast cancer.  The drug is approved as monotherapy for adult patients who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six… Read More

#Cancer Research #Editor's Choice #News

Child with cystic fibrosis on ventilator
#Cell and gene therapy #Cystic fibrosis #European Commission #Gene therapy #Krystal Biotech #Orphan drugs

Gene therapy for cystic fibrosis receives EC orphan drug designation

The European Commission has granted orphan designation for Krystal Biotech’s KB407 for the treatment of cystic fibrosis (CF).  KB407 is an investigational, redosable gene therapy designed to correct the underlying cause of cystic fibrosis by delivering two copies of the CFTR gene directly to the airway epithelial cells when delivered… Read More

#News #Regulatory

EU flag
#Advanced Therapy Medicinal Products (ATMPs) #Alliance for Regenerative Medicine #Cell and gene therapy #EFPIA #EU #European Commission #European Federation of Pharmaceutical Industries and Associations #Market reporting

Can Europe become a major player in cell and gene therapy?

With European life sciences R&D investment at a 20-year low, biopharmaceutical associations and MEPs are calling on the EU to modernise its policies. DDW’s Diana Spencer asks what will be needed for Europe to compete in the growing global market for advanced therapies.  A new report by Charles River Associates… Read More

#Exclusive Content #Market Reports

Scientist filling test tubes in biotechnologymlab
#Biologics / Biotechnology #EIT Health #European Commission #Investment #Regulatory #Start-ups

Partnership supports biotech start-ups on journey to market

ProductLife Group has been chosen as the exclusive Privileged Partner for Regulatory & Compliance services by EIT Health’s Venture Centre of Excellence (VCoE). The partnership means EIT Health will… Read More

#News

Polyneuropathy
#European Commission #hATTR amyloidosis #Orphan drugs

RNAi therapeutic approved in EU for hATTR amyloidosis

The European Commission (EC) has granted marketing authorisation for Alnylam Pharmaceuticals’ AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis. The RNAi therapeutic has been approved in adult patients with stage 1 or stage 2 polyneuropathy, following positive 18-month results from the HELIOS-A Phase III study. AMVUTTRA significantly improved… Read More

#News #Regulatory

#European Commission #Kidney disease #Nephrology #Orphan drugs

EC approves first treatment for rare kidney disease

Nefecon has become the first and only approved treatment in the EU for primary immunoglobulin A nephropathy (IgAN), a rare, progressive kidney disease. The European Medicines Agency said that the medicine “was shown to be effective at lowering the level of excess protein in the urine in patients with IgAN,… Read More

#News #Regulatory

Human kidneys
#Autoimmune disease #European Commission #Human trials #Lupus

EU approval for first oral treatment for lupus nephritis

Otsuka Pharmaceutical’s Lupkynis (voclosporin) is the first oral treatment to be approved in Europe for the treatment of active lupus nephritis (LN) in adult patients. The drug has received approval from the European Commission (EC) in combination with mycophenolate mofetil (MMF) for the treatment of adult patients with active class… Read More

#News #Regulatory

Chronic myeloid leukaemia
#Cancer research #European Commission #Leukaemia #Novartis #Orphan drugs #Scemblix #STAMP inhibitor

European Commission approval for chronic myeloid leukaemia drug

The European Commission (EC) has approved orphan drug Scemblix (asciminib), providing a new treatment option for patients who are intolerant or resistant to tyrosine kinase inhibitors (TKIs). It is approved to treat adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase who have been previously treated with two or more… Read More

#Cancer Research #News

#CAR-T #European Commission #Oncology

European Commission approves Yescarta  

The European Commission (EC) has approved biotechnology company Kite’s CAR T-cell therapy Yescarta for patients with follicular lymphoma (FL).  Specifically the approval is for adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.  The approval was based… Read More

#News